Sickle Cell Clinical Trials

164 recruitingLast updated: May 13, 2026

There are 164 actively recruiting sickle cell clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Chicago, Illinois, United States, Atlanta, Georgia, United States, Memphis, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Sickle Cell Trials at a Glance

164 actively recruiting trials for sickle cell are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 52 trials, with the heaviest enrollment activity in Chicago, Atlanta, and Memphis. Lead sponsors running sickle cell studies include St. Jude Children's Research Hospital, Children's Hospital Medical Center, Cincinnati, and Assistance Publique - Hôpitaux de Paris.

Browse sickle cell trials by phase

Treatments under study

About Sickle Cell Clinical Trials

Looking for clinical trials for Sickle Cell? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Sickle Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Sickle Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 164 trials

Recruiting
Phase 1Phase 2

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sickle Cell Disease
Novartis Pharmaceuticals161 enrolled3 locationsNCT06546670
Recruiting
Phase 2

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Sickle Cell Disease
CSL Behring63 enrolled5 locationsNCT07224360
Recruiting

Blood Sampling for Research Related to Sickle Cell Disease

Sickle Cell DiseaseSickle Cell TraitSickle Cell Anemia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)250 enrolled1 locationNCT00542230
Recruiting
Phase 1

Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease

Sickle Cell Disease
City of Hope Medical Center11 enrolled1 locationNCT03279094
Recruiting
Phase 1

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease
Disc Medicine, Inc24 enrolled5 locationsNCT07187973
Recruiting
Not Applicable

A Socio-ecological Approach for Improving Self-management in Adolescents With SCD

Anemia, Sickle Cell
Children's Hospital Medical Center, Cincinnati310 enrolled4 locationsNCT06290401
Recruiting
Not Applicable

SickleFit Exercise and Nutrition Study

Sickle Cell DiseaseAging
Duke University40 enrolled1 locationNCT07442851
Recruiting
Phase 1

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell DiseaseHb-SS DiseaseHemoglobin S+3 more
National Heart, Lung, and Blood Institute (NHLBI)25 enrolled1 locationNCT05904093
Recruiting
Phase 2

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

Sickle Cell Disease
St. Jude Children's Research Hospital40 enrolled1 locationNCT05583721
Recruiting

Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

Sickle Cell Disease
St. Jude Children's Research Hospital145 enrolled1 locationNCT05810181
Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

Sickle Cell DiseaseMalariaAlpha and Beta Thalassemia+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT03937817
Recruiting
Not Applicable

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

Sickle Cell Disease
Boston Children's Hospital25 enrolled1 locationNCT06555939
Recruiting
Phase 3

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Sickle Cell Disease
Sanofi192 enrolled54 locationsNCT06975865
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sickle Cell Disease
Novartis Pharmaceuticals315 enrolled31 locationsNCT06439082
Recruiting
Not Applicable

Predictors of Pain in Sickle Cell Disease

Chronic PainSickle Cell Disease
Duke University70 enrolled1 locationNCT06139510
Recruiting
Phase 1

Gene Editing For Sickle Cell Disease

Sickle Cell Disease
St. Jude Children's Research Hospital25 enrolled1 locationNCT06506461
Recruiting

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Sickle Cell Disease
St. Jude Children's Research Hospital352 enrolled1 locationNCT04416178
Recruiting
Phase 2

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Sickle Cell Disease Vaso-occlusive Crisis
CSL Behring70 enrolled17 locationsNCT06699849
Recruiting
Phase 1Phase 2

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

Sickle Cell DiseaseGraft FailureHematopoetic Stem Cell Transplant+2 more
University of Colorado, Denver24 enrolled4 locationsNCT07252050
Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354